整合缓解持续时间的贝叶斯分层II期癌症临床试验监查设计
针对单臂II期癌症临床试验,提出一种贝叶斯分层无效性监查设计,将缓解持续时间(DOR)信息纳入监查规则。第一层评估缓解率是否支持继续试验,若不支持则触发基于DOR的第二层监查,两层均满足才因无效停止。模拟研究评估了操作特征,并以纳武利尤单抗联合阿扎胞苷治疗复发/难治性急性髓系白血病的单臂II期试验进行示例。
要点
- 该设计在缓解率未改善但DOR显著延长时,避免因无效而过早终止试验。
- 监查规则分两层:先评估缓解率,再基于DOR触发第二层无效性停止。
- 通过模拟研究比较了所提规则与标准方法的操作特征。
核心结论
- 所提贝叶斯分层监查设计可避免在实验性治疗显著延长DOR但未改善缓解率时因无效而激进地早期终止试验。
研究设计与样本
- 提出一种用于单臂II期癌症临床试验的贝叶斯分层无效性监查设计,纳入缓解持续时间信息。
- 通过模拟研究评估所提监查规则的操作特征,并与标准方法比较。
- 以纳武利尤单抗联合阿扎胞苷治疗复发/难治性急性髓系白血病的单臂II期试验示例所提设计。
主要发现
- 第一层监查评估缓解率是否提供证据表明实验性治疗值得进一步评估。
- 若缓解率证据不支持继续试验,则触发基于DOR的第二层监查规则。
- 若两条停止规则均满足,试验将因无效而停止。
临床怎么用
- 在单臂II期癌症试验中,可考虑采用分层监查规则,同时关注缓解率和缓解持续时间。
- 当靶向药物缓解率相似但缓解持续时间较长时,该设计有助于避免过早终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We propose a Bayesian hierarchical monitoring design for single-arm phase II clinical trials of cancer treatments that incorporates the information on the duration of response (DOR) into the monitoring rules. To screen a new treatment by evaluating its preliminary therapeutic effect, futility monitoring rules are commonly used in phase II clinical trials to make "go/no-go" decisions timely and efficiently. These futility monitoring rules are usually focused on a single outcome (eg, response rate), although a single outcome may not adequately determine the efficacy of the experimental treatment. For example, targeted agents with a long response duration but a similar response rate may be worth further evaluation in cancer research. To address this issue, we propose Bayesian hierarchical futility monitoring rules to consider both the response rate and duration. The first level of monitoring evaluates whether the response rate provides evidence that the experimental treatment is worthy of further evaluation. If the evidence from the response rate does not support continuing the trial, the second level monitoring rule, which is based on the DOR, will be triggered. If both stopping rules are satisfied, the trial will be stopped for futility. We conducted simulation studies to evaluate the operating characteristics of the proposed monitoring rules and compared them to those of standard method. We illustrated the proposed design with a single-arm phase II cancer clinical trial to assess the safety and efficacy of combined treatment of nivolumab and azacitidine in patients with relapsed/refractory acute myeloid leukemia. The proposed design avoids an aggressive early termination for futility when the experimental treatment substantially prolongs the DOR but fails to improve the response rate.
引用
- Wang J, Ma J, Cai C, et al. A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules. Stat Med. 2021. PMID: 34101217. doi:10.1002/sim.9084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。